Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

NCT01480219 · clinicaltrials.gov ↗

COMPLETED

Status

467

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Melanoma Skin Carcinoma

Interventions

DRUG: voriconazole (Vfend)
OTHER: no voriconazole (Vfend)

Sponsor

Pfizer

Collaborators

[object Object]